Colorectal Cancer: A Rising Threat to Younger Adults

Colorectal cancer is increasingly affecting individuals under 50, now standing as the leading cause of cancer-related death in this age group in the United States. This alarming trend demands urgent action, from improved early detection methods to accelerated development of innovative therapies.

A Shift in Cancer Demographics

For decades, declining cancer death rates offered a hopeful narrative. However, this progress has not been uniform. While deaths from cancers like lung, breast and leukemia have decreased over the past three decades, colorectal cancer mortality in adults under 50 has steadily increased since 2005. Data published in JAMA in 2026 confirms this concerning shift [1]. In the early 1990s, colorectal cancer ranked fifth in cancer-related deaths among those under 50; by 2023, it had risen to first place.

The Impact on Younger Patients

Between 1990 and 2023, overall cancer deaths among adults under 50 fell by 44%. However, colorectal cancer bucked this trend. This disease is now diagnosed in individuals in their 30s and 40s, often at an advanced stage – nearly three out of four cases are diagnosed when the cancer has already spread [3]. This late-stage diagnosis leads to significant challenges, including concerns about fertility, the burden of intensive treatment, financial strain, and long-term physical complications that can disrupt careers and quality of life. This is not solely a medical issue, but a public health and economic one.

Current Screening and Detection

Current screening guidelines recommend starting regular screenings at age 45 for individuals at average risk. Increased awareness of warning signs, such as blood in the stool or persistent abdominal pain, is also crucial for earlier detection. However, detection alone is insufficient to reverse this trend.

The Challenge of MSS Colorectal Cancer

More than 90% of colorectal cancers, particularly those that have spread (metastatic), are classified as microsatellite stable (MSS), or pMMR. These tumors have historically been less responsive to immunotherapy. Only a minor percentage (5-10%) are MSI-high or dMMR, and patients with these types often experience dramatic responses to existing immunotherapy treatments [3].

The Need for Immunotherapy Innovation

Traditional treatments for MSS colorectal cancer – chemotherapy, radiation, and surgery – can be effective, but often come with significant side effects, including neuropathy, bowel problems, infertility, and reduced quality of life. Advancements in immunotherapy are showing promise, even in these historically difficult-to-treat MSS tumors. Agenus is dedicated to advancing immunotherapy research to expand treatment options and improve outcomes for patients across all age groups [1].

Accelerating Progress

Addressing this crisis requires a multi-faceted approach: accelerating the development of new therapies, streamlining the evaluation process for innovative treatments, ensuring responsible global access, investing in prevention and early detection, and fostering collaboration among regulators, clinicians, industry, and patient advocates.

Looking Ahead

Colorectal cancer should not be the leading cause of cancer death for adults under 50. The current reality demands immediate and decisive action. The time for incremental changes has passed; a concerted effort to accelerate progress is essential to improve outcomes and save lives. Agenus recently highlighted the urgency of the situation following discussions with patients and advocates in Washington [2].